Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ceftazidime. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 3/20 | 0.58 |
| ▸ | PGR | P06401 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 2/20 | 0.58 |
| ▸ | ESR1 | P03372 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | APEX1 | P27695 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.43 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Moxalactam SCHEMBL28086495 | 0.89 | NR1I2 (0.69) | NR1I2PGRPPARGTDP1HSD17B10 | |
| Moxalactam SCHEMBL6521966 | 0.86 | NR1I2 (0.64) | NR1I2PGRPPARGTDP1HSD17B10 | |
| Ceftriaxone SCHEMBL3389557 | 0.86 | NR1I2 (0.64) | NR1I2PGRPPARGTDP1HSD17B10 | |
| Moxalactam SCHEMBL13723425 | 0.84 | PTGS1 (0.64) | NR1I2PGRPPARGTDP1HSD17B10 | |
| Ceftazidime SCHEMBL9867976 | 0.83 | NR1I2 (0.69) | NR1I2PGRPPARGESR1TDP1 | |
| Moxalactam SCHEMBL22205083 | 0.82 | NR1I2 (0.52) | NR1I2PGRPPARGESR1TDP1 | |
| Cefoperazone SCHEMBL1963141 | 0.81 | TDP1 (0.65) | NR1I2PGRPPARGESR1TDP1 | |
| SCHEMBL11470422 | 0.78 | NR1I2 (0.85) | NR1I2PGRPPARGESR1TDP1 | |
| SCHEMBL11473844 | 0.78 | NR1I2 (0.85) | NR1I2PGRPPARGESR1TDP1 | |
| Ceftazidime SCHEMBL8681094 | 0.77 | NR1I2 (0.74) | NR1I2PGRPPARGESR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036200-B2 | Bismuth-thiol compositions and methods for treating wounds | MICROBION CORPORATION (US) | 2024-07-16 | — | — | US | disclosed |
| US-20240173369-A1 | PSEUDOMONAS BACTERIOPHAGE AND USES THEREOF | BIOMX LTD. (IL) | 2024-05-30 | — | — | US | disclosed |
| US-11974978-B2 | Bismuth-thiol compositions and methods for treating wounds | MICROBION CORPORATION (US) | 2024-05-07 | — | — | US | disclosed |
| EP-4337764-A1 | STAPHYLOCOCCUS BACTERIOPHAGE AND USES THEREOF | Biomx Ltd. (IL) | 2024-03-20 | — | — | EP | disclosed |
| US-20240075084-A1 | KLEBSIELLA BACTERIOPHAGE AND USES THEREOF | BIOMX LTD. (IL) | 2024-03-07 | — | — | US | disclosed |
| EP-4332217-A2 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | Technophage, Investigação e Desenvolvimento em Biotecnologia, SA (PT) | 2024-03-06 | — | — | EP | disclosed |
| EP-4313091-A1 | PSEUDOMONAS BACTERIOPHAGE AND USES THEREOF | Biomx Ltd. (IL) | 2024-02-07 | — | — | EP | disclosed |
| US-20230390349-A1 | FUSOBACTERIUM BACTERIOPHAGE AND USES THEREOF | BIOMX LTD. (IL) | 2023-12-07 | — | — | US | disclosed |
| EP-4281094-A1 | KLEBSIELLA BACTERIOPHAGE AND USES THEREOF | Biomx Ltd. (IL) | 2023-11-29 | — | — | EP | disclosed |
| EP-3650034-B1 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | TECHNOPHAGE INVESTIG E DESENVOLVIMENTO EM BIOTECNOLOGIA SA (PT) | 2023-09-20 | — | — | EP | disclosed |
| CN-104519893-A | Compositions comprising a mixture of antibacterial bacteriophages for the treatment of bacterial infections and methods of use thereof | TECNIFAR IND TECNICA FARMACEUTICA SA | 2015-04-15 | — | — | CN | disclosed |
| EP-2833899-A1 | COMPOSITIONS COMPRISING COCKTAILS OF ANTIBACTERIAL PHAGES AND USES THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | Tecnifar-Indústria Técnica Farmacêutica, S.A. (PT) | 2015-02-11 | — | — | EP | disclosed |
| US-20140079671-A1 | Antibacterial Phage, Phage Peptides And Methods Of Use Thereof | TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT) | 2014-03-20 | — | — | US | disclosed |
| WO-2013141730-A1 | COMPOSITIONS COMPRISING COCKTAILS OF ANTIBACTERIAL PHAGES AND USES THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS | TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A. (PT) | 2013-09-26 | — | — | WO | disclosed |
| EP-2616087-A2 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | Tecnifar-Indústria Técnica Farmacêutica, S.A. (PT) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012036580-A2 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | TECNIFAR-INDÚSTRIA TÉCNICA FARMACÊUTICA, S.A. (PT) | 2012-03-22 | — | — | WO | disclosed |
| US-20120052048-A1 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | TECNIFAR-INDUSTRIA TECNICA FARMACEUTICA, S.A. (PT) | 2012-03-01 | — | — | US | disclosed |
| CN-102348460-A | Antibacterial bacteriophages, bacteriophage peptides and methods of use thereof | TECNIFAR IND TECNICA FARMACEUTICA S A | 2012-02-08 | — | — | CN | disclosed |
| EP-2393502-A2 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA (PT) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010090542-A2 | ANTIBACTERIAL PHAGE, PHAGE PEPTIDES AND METHODS OF USE THEREOF | TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11974978-B2 | Bismuth-thiol compositions and methods for treating wounds | TST, CBS, CTH | NR1I2 4147/4885PGR 4540/4885PPARG 3136/4885 |
| US-12036200-B2 | Bismuth-thiol compositions and methods for treating wounds | TST, CBS, CTH | NR1I2 4147/4885PGR 4540/4885PPARG 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.